Trial · NCT02168777
Results by group97
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 97
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Maximum Drug Concentration in Plasma After Multiple Dose (Cmax,md) for Refametinib | Ph1b-Refametinib/Regorafenib Cohort 0 | NA | Geometric Coefficient of Variation NA | μg/L | |
| Maximum Drug Concentration in Plasma After Multiple Dose (Cmax,md) for Refametinib | Ph1b-Refametinib/Regorafenib Cohort -1 | 315.9 | Geometric Coefficient of Variation 43 | μg/L | |
| Maximum Drug Concentration in Plasma After Multiple Dose (Cmax,md) for Refametinib | Ph1b-Refametinib/Regorafenib Cohort -1a | 390.7 | Geometric Coefficient of Variation 52 | μg/L | |
| Maximum Drug Concentration in Plasma After Multiple Dose (Cmax,md) for Refametinib Metabolite M-11 | Ph1b-Refametinib/Regorafenib Cohort 0 | NA | Geometric Coefficient of Variation NA | μg/L | |
| Maximum Drug Concentration in Plasma After Multiple Dose (Cmax,md) for Refametinib Metabolite M-11 | Ph1b-Refametinib/Regorafenib Cohort -1 | 104.9 | Geometric Coefficient of Variation 36 | μg/L | |
| Maximum Drug Concentration in Plasma After Multiple Dose (Cmax,md) for Refametinib Metabolite M-11 | Ph1b-Refametinib/Regorafenib Cohort -1a | 112.3 | Geometric Coefficient of Variation 44 | μg/L | |
| Area Under the Plasma Concentration-time Curve From 0 to 12 h After Multiple Dose (AUC(0-12)md) for Refametinib | Ph1b-Refametinib/Regorafenib Cohort 0 | NA | Geometric Coefficient of Variation NA | μg*h/L | |
| Area Under the Plasma Concentration-time Curve From 0 to 12 h After Multiple Dose (AUC(0-12)md) for Refametinib | Ph1b-Refametinib/Regorafenib Cohort -1 | 2399.2 | Geometric Coefficient of Variation 65 | μg*h/L | |
| Area Under the Plasma Concentration-time Curve From 0 to 12 h After Multiple Dose (AUC(0-12)md) for Refametinib | Ph1b-Refametinib/Regorafenib Cohort -1a | 3632.3 | Geometric Coefficient of Variation 51 | μg*h/L | |
| Area Under the Plasma Concentration-time Curve From 0 to 12 h After Multiple Dose (AUC(0-12)md) for Refametinib Metabolite M-11 | Ph1b-Refametinib/Regorafenib Cohort 0 | NA | Geometric Coefficient of Variation NA | μg*h/L | |
| Area Under the Plasma Concentration-time Curve From 0 to 12 h After Multiple Dose (AUC(0-12)md) for Refametinib Metabolite M-11 | Ph1b-Refametinib/Regorafenib Cohort -1 | 1013.4 | Geometric Coefficient of Variation 40 | μg*h/L | |
| Area Under the Plasma Concentration-time Curve From 0 to 12 h After Multiple Dose (AUC(0-12)md) for Refametinib Metabolite M-11 | Ph1b-Refametinib/Regorafenib Cohort -1a | 1144.7 | Geometric Coefficient of Variation 39 | μg*h/L | |
| Maximum Drug Concentration in Plasma After Multiple Dose (Cmax,md) for Regorafenib | Ph1b-Refametinib/Regorafenib Cohort 0 | NA | Geometric Coefficient of Variation NA | μg/L | |
| Maximum Drug Concentration in Plasma After Multiple Dose (Cmax,md) for Regorafenib | Ph1b-Refametinib/Regorafenib Cohort -1 | 1966.0 | Geometric Coefficient of Variation 17 | μg/L | |
| Maximum Drug Concentration in Plasma After Multiple Dose (Cmax,md) for Regorafenib | Ph1b-Refametinib/Regorafenib Cohort -1a | 2206.4 | Geometric Coefficient of Variation 34 | μg/L | |
| Maximum Drug Concentration in Plasma After Multiple Dose (Cmax,md) for Regorafenib Metabolite M-2 | Ph1b-Refametinib/Regorafenib Cohort 0 | NA | Geometric Coefficient of Variation NA | μg/L | |
| Maximum Drug Concentration in Plasma After Multiple Dose (Cmax,md) for Regorafenib Metabolite M-2 | Ph1b-Refametinib/Regorafenib Cohort -1 | 1409.1 | Geometric Coefficient of Variation 20 | μg/L | |
| Maximum Drug Concentration in Plasma After Multiple Dose (Cmax,md) for Regorafenib Metabolite M-2 | Ph1b-Refametinib/Regorafenib Cohort -1a | 1642.7 | Geometric Coefficient of Variation 98 | μg/L | |
| Maximum Drug Concentration in Plasma After Multiple Dose (Cmax,md) for Regorafenib Metabolite M-5 | Ph1b-Refametinib/Regorafenib Cohort 0 | NA | Geometric Coefficient of Variation NA | μg/L | |
| Maximum Drug Concentration in Plasma After Multiple Dose (Cmax,md) for Regorafenib Metabolite M-5 | Ph1b-Refametinib/Regorafenib Cohort -1 | 1148.8 | Geometric Coefficient of Variation 90 | μg/L |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02168777/results